… and therapeutic response of glioma patients. We used publicly available clinical data sets
from large cohorts of glioma patients to … of glioma patients to molecularly targeted therapeutics. …

… Malignant gliomas are the third leading cause of cancer death in people aged 15 to 34 years
… Gliomas are more common in developed countries than in developing countries [24], which …

… in benign and malignant gliomas and contraindications to the use … , and assessment of
therapeutic responses of gliomas. … associated with gliomas using metabolic mapping on 7T MRS/I …

… Malignant gliomas typically contain both neoplastic cells and … ; and (iii) glioblastoma NOS,
for which full IDH evaluation … differ in prognosis and therapy response. Primary glioblastomas …

… In addition, EOR was significantly less in group 2 (70% vs 89% in group 1, p = 0.003), which
is consistent with a lower plastic potential due to a higher rate of malignant gliomas in group …

… by different machine learning approaches for patients with malignant glioma and metastases.
… If these maps were routinely available, postoperative radiotherapy of malignant glioma …

… maps, we sought to explore the effect of tumor location on overall survival in a population-based
cohort of patients with glioblastoma … These patients are treated as grade IV glioma at our …

… The standard treatment for GBMs is surgical resection followed by … of glioblastoma cells
and glioma initiating cells (GICs), respectively, promote resistance against all current treatment …

… for glioma patients includes 20 min for daily patient setup and … This condition reflects therapy
response with recruitment of … and Proton Density (PD) maps in patients with GBM after each …

… in glioblastoma (GBM) is important for therapeutic stratification and helps predict treatment
response … the fragments per kilobase of transcripts per million mapped reads (FPKM) [41] to …